fibronectin type III domain containing 3BGenealiases: FAD104 · PRO4979 · YVTM2421
Q-omics provides the consensus-scored FNDC3B profile across patient tissues and cancer cell-line models. FNDC3B expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FNDC3B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FNDC3B protein abundance shows 29,759 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where FNDC3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FNDC3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FNDC3B survival associations across molecular data types. FNDC3B RNA expression shows survival associations in the most cancer types (30), followed by mutation status (12) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FNDC3B RNA expression–survival associations across cancer types. High FNDC3B expression shows unfavorable associations in MESO, BLCA, LIHC, ACC and LGG, but favorable associations in SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for FNDC3B RNA expression.
This table summarizes FNDC3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FNDC3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FNDC3B shows higher tumor expression in HNSC, KIRC, STAD, KIRP, LUAD and LIHC. The HNSC box plot shows higher FNDC3B RNA expression in tumor versus normal tissue (log2 FC = +2.371, t-test p < 0.001).
This table shows molecular features associated with FNDC3B in patient tissues and cancer cell lines. In patient samples, FNDC3B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FNDC3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
